Clinical Trial Update: Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition [Phase 2]

View source ↗

Summary

Phase 2 trial update for AVP-786 in disinhibition syndrome, focusing on safety, tolerability, and efficacy; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Disinhibition Syndrome

Drugs mentioned

• AVP-786 (deudextromethorphan hydrobromide/quinidine sulfate)

Snippet

Sponsor: Avanir Pharmaceuticals | Conditions: Disinhibition Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2020-10-26